Light-Chain Deposition Disease Successfully Treated with Bortezomib in an Elderly Patient: A Case Report and Review of the Literature

Intern Med. 2015;54(22):2893-8. doi: 10.2169/internalmedicine.54.4994. Epub 2015 Nov 15.

Abstract

We herein report the case of an elderly patient with light-chain deposition disease (LCDD) successfully treated with bortezomib. An 83-year-old woman was admitted because of nephrotic syndrome. She was diagnosed to have monoclonal gammopathy of undetermined significance (IgG-κ type) and LCDD, on the basis of serum and urinary immunoelectrophoresis and renal biopsy. She responded to a modified regimen of bortezomib-based chemotherapy with disappearance of proteinuria without any adverse effects. According to a literature review of 16 cases, including the present case, bortezomib-based chemotherapy appears to be a convincing strategy for the treatment of LCDD even in elderly patients.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Aged, 80 and over
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Bortezomib / therapeutic use*
  • Female
  • Humans
  • Immunoglobulin Light Chains / metabolism*
  • Monoclonal Gammopathy of Undetermined Significance / diagnosis*
  • Monoclonal Gammopathy of Undetermined Significance / pathology
  • Nephrotic Syndrome / etiology*
  • Nephrotic Syndrome / pathology
  • Nephrotic Syndrome / urine
  • Proteinuria / etiology*
  • Remission Induction
  • Treatment Outcome

Substances

  • Antineoplastic Agents, Alkylating
  • Immunoglobulin Light Chains
  • Bortezomib